Australian biotech company loses SIAC claim
Credit: iStockphoto/RGtimeline
An Australian biotechnology company has lost a US$300 million SIAC claim over the development of a medicine designed to treat skin and bloodstream infections.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Upgrade now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10